| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
13,870,000 |
| Market
Cap: |
583.93(M) |
| Last
Volume: |
2,897,500 |
Avg
Vol: |
64,821 |
| 52
Week Range: |
$17.67 - $38.49 |
|
| Level
I Sector: |
Basic Materials |
| Level
II Sector: |
Chemicals |
| Level
III Sector: |
Specialty Chemicals |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Surmodics is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Co.'s segments are: Medical Device, which develops and manufactures vascular intervention medical device products and is engaged in Co.'s proprietary surface modification coating technologies that impart lubricity, pro-healing, biocompatibility characteristics, or drug-delivery capabilities to medical devices and delivery systems; and IVD, which manufactures and sells components for IVD immunoassay and molecular tests within the diagnostic, biomedical research, and life science markets.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,872 |
| Total Sell Value |
$0 |
$0 |
$0 |
$335,339 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lehman Mark A. |
Corporate Controller |
• – – |
2010-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
6,263 |
|
- |
|
| Ramius Capital Group Llc |
10% Owner |
– – • |
2010-11-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,088,760 |
|
- |
|
| Cowen Overseas Investment Lp |
10% Owner |
– – • |
2010-11-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,088,760 |
|
- |
|
| Phillips Bryan K |
SVP, Gen Counsel & Secretary |
• – – |
2010-09-19 |
4 |
D |
$10.93 |
$7,148 |
D/D |
(654) |
7,326 |
|
- |
|
| Middleton John C. |
VP, Drug Del, Product Dev |
• – – |
2010-07-31 |
4 |
D |
$13.12 |
$8,279 |
D/D |
(631) |
1,643 |
|
- |
|
| Tipton Arthur J |
VP, Pres of Pharmaceuticals |
• – – |
2010-07-31 |
4 |
D |
$13.12 |
$57,977 |
D/D |
(4,419) |
17,317 |
|
- |
|
| Phillips Bryan K |
VP, Gen Counsel & Secretary |
• – – |
2010-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,980 |
7,980 |
|
- |
|
| Olson Charles W |
Senior VP, Bus Dev & Mkting |
• – – |
2010-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,980 |
12,591 |
|
- |
|
| Ankeny Philip D |
Interim CEO, Senior VP & CFO |
• – – |
2010-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,980 |
36,369 |
|
- |
|
| Lehman Mark A. |
Corporate Controller |
• – – |
2010-05-19 |
4 |
D |
$17.47 |
$2,254 |
D/D |
(129) |
1,263 |
|
- |
|
| Robey Brian L |
Sr VP, Product Development |
• – – |
2010-05-16 |
4 |
D |
$18.01 |
$13,814 |
D/D |
(767) |
1,233 |
|
- |
|
| Middleton John C. |
VP, Drug Del, Product DevOffic |
• – – |
2010-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,274 |
|
- |
|
| Stich Joseph J. |
VP, Corp Dev & Strat Planning |
• – – |
2010-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
| Rusch Eugene C. |
VP, Manufacturing |
• – – |
2010-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Meslow John A |
Director |
– • – |
2010-03-09 |
4 |
D |
$20.76 |
$140,607 |
D/D |
(6,773) |
31,227 |
|
- |
|
| Meslow John A |
Director |
– • – |
2010-03-09 |
4 |
OE |
$14.06 |
$140,625 |
D/D |
10,000 |
38,000 |
|
- |
|
| Lopez Paul A |
VP, President - Ophthamology |
• – – |
2009-11-30 |
4 |
S |
$22.23 |
$111,150 |
D/D |
(5,000) |
9,005 |
|
- |
|
| Lopez Paul A |
VP, President - Ophthamology |
• – – |
2009-11-30 |
4 |
D |
$22.35 |
$59,004 |
D/D |
(2,640) |
14,005 |
|
- |
|
| Lopez Paul A |
VP, President - Ophthamology |
• – – |
2009-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
16,645 |
|
- |
|
| Shoup Michael J |
VP of Qual, Reg & Clinical |
• – – |
2009-11-20 |
4 |
S |
$22.90 |
$80,153 |
D/D |
(3,500) |
2,851 |
|
- |
|
| Anderson Aron B |
VP & Chief Scientific Officer |
• – – |
2009-11-17 |
4 |
S |
$23.43 |
$101,218 |
D/D |
(4,320) |
33,867 |
|
- |
|
| Phillips Bryan K |
VP, Gen Counsel & Secretary |
• – – |
2009-11-16 |
4 |
S |
$23.95 |
$36,581 |
D/D |
(1,527) |
2,000 |
|
- |
|
| Olson Charles W |
VP & Gen Mgr - Cardiovascular |
• – – |
2009-11-16 |
4 |
S |
$23.75 |
$261,650 |
D/D |
(10,996) |
6,611 |
|
- |
|
| Ankeny Philip D |
Senior VP & CFO |
• – – |
2009-11-15 |
4 |
D |
$23.38 |
$76,453 |
D/D |
(3,270) |
28,958 |
|
- |
|
| Olson Charles W |
VP & Gen Mgr - Cardiovascular |
• – – |
2009-11-15 |
4 |
D |
$23.38 |
$38,226 |
D/D |
(1,635) |
17,607 |
|
- |
|
888 Records found
|
|
Page 27 of 36 |
|
|
7.00 (19.94%) 
